Page 81 - journal-7-1-Full
P. 81

Journal of Thai Traditional & Alternative Medicine                         Vol. 7 No. 1 January-April 2009 ˜Û



                 Ò. ªí®®—¬ “‡Àμÿ·Ωß (predisposing factor) ∑’ˇªìπ    Û. ªí®®—¬∑ÿ쑬¿Ÿ¡‘À√◊Õªí®®—¬Àπÿπ (secondary or pre-

              “‡ÀμÿÀ≈—°¢Õß‚√§π’È ‰¥â·°à æ—π∏ÿ°√√¡ ‚¥¬ºŸâªÉ«¬¿“«–¿Ÿ¡‘·æâ  cipitating factors) ‰¥â·°à ‡Àμÿ∑’ËÀπÿπ„Àâ· ¥ßÕ“°“√ÕÕ°¡“
             (atopy) ¡’§«“¡º‘¥ª√°μ‘¢ÕßÀπ૬æ—π∏ÿ°√√¡μÕ∫ πÕß     À√◊Õ„Àâ¡’Õ“°“√¡“°¢÷È𠇙àπ ‚√§μ‘¥‡™◊ÈÕ,  “√√–§“¬‡§◊Õßμà“ßÊ
             (immune response gene; IR - gene) ´÷Ëß∑”Àπâ“∑’˧«∫§ÿ¡  (°≈‘Ëπ©ÿπ, §«—πμà“ß Ê, ΩÿÉπ≈–ÕÕß∑ÿ°ª√–‡¿∑), °“√ÕÕ°°”≈—ß

             °“√ √â“ß¿Ÿ¡‘§ÿâ¡°—π¢Õß√à“ß°“¬. Àπ૬æ—π∏ÿ°√√¡∑’˺‘¥ª√°μ‘π’È  °“¬, °“√‡ª≈’ˬπ·ª≈ßÕÿ≥À¿Ÿ¡‘Õ¬à“ß√«¥‡√Á«, ªí®®—¬∑“ß®‘μ ‡™àπ
                                       ÒÒ
              “¡“√∂∂à“¬∑Õ¥‰ª¬—ß≈Ÿ°À≈“π‰¥â                       §«“¡‡§√’¬¥, §«“¡«‘μ°°—ß«≈, §«“¡º‘¥ª√°μ‘∑“ß°“¬«‘¿“§
                 Ú. ªí®®—¬ “‡Àμÿª∞¡¿Ÿ¡‘À√◊Õ “‡Àμÿ®”‡æ“– (primary or  „π®¡Ÿ° ‚¥¬‡©æ“–ºπ—ß°—Èπ™àÕß®¡Ÿ°§¥À√◊Õ¡’‡¥◊Õ¬¬◊Ëπ.

             specific factor) ‡ªì𠓇Àμÿ‚¥¬μ√ß.  ‘Ëß∑’˺ŸâªÉ«¬·æâ À√◊Õ “√  ‡√‘Ë¡®“°√–¬–°àÕ¿Ÿ¡‘‰« (sensitization phase) ·≈â«
             °àÕ¿Ÿ¡‘·æâ (antigen, allergen) ™π‘¥∑’˰àÕÕ“°“√‰¥â∫àÕ¬§◊Õ  μ“¡¥â«¬√–¬–Õ“°“√∑“ß§≈‘π‘° (clinical phase) (√Ÿª∑’Ë Ú).  ‚¥¬

              “√°àÕ¿Ÿ¡‘·æâ„πÕ“°“» (aeroallergen) ∑’ˇ¢â“ Ÿà√à“ß°“¬‚¥¬  ºŸâªÉ«¬∑’Ë¡’æ—π∏ÿ°√√¡‚π⡇Ւ¬ß∑’Ë®–‡ªìπ‚√§¿Ÿ¡‘·æâ ¡’°“√ √â“ß IgE
             °“√À“¬„® ‡™àπ ΩÿÉπ∫â“π, ‰√ΩÿÉπ∫â“π, ‡° √æ◊™, ™‘Èπ à«π À√◊Õ  ‡¡◊ËÕ —¡º—  “√°àÕ¿Ÿ¡‘·æâ ‡√’¬°«à“ ç°“√°àÕ¿Ÿ¡‘‰« (sensitization)é.
              ‘Ëߢ—∫∂à“¬¢Õß·¡≈ß∑’ËÕ“»—¬Õ¬Ÿà„π∫â“𠇙àπ ·¡≈ß “∫, ¬ÿß,  À≈—ß®“°π—Èπ ‡´≈≈几πÕ·Õπ쑇®π (antigen-presenting cells)

             ·¡≈ß«—π, ¡¥.  “√°àÕ¿Ÿ¡‘·æâ∑’Ë ”§—≠∑’Ë ÿ¥„πΩÿÉπ §◊Õμ—«‰√ΩÿÉπ  ‡™àπ ·¡‚§√‡ø® À√◊Õ‡´≈≈凥π¥√‘μ‘° (dendritic cells) ®–
             ´÷Ëß “√°àÕ¿Ÿ¡‘·æâπ—Èπ ¡’Õ¬Ÿà„πμ—«‰√·≈–„π ‘Ëߢ—∫∂à“¬¢Õß¡—π.  π”·Õπ쑇®π‰ª‡ πÕ„À⇴≈≈凌≈‡ªÕ√å∑’ (T-helper cells; TH





                                                      欓∏‘ √’√«‘∑¬“
                               Phase 1:                                 Phase 2:

                         Sensitization phase                         Clinical phase




                                                     Early-phase response           Late-phase response

                     Antigen     Antigen- presenting cell         • Induction of adhesion  molecules
                                                         Antigen
                                                                  • Cellular infiltration

                                                              Ig E                Late-phase
                                           Processed             Mast cell
                                           antigen                                reaction  Hyper-
                                                                                          responsiveness
                                                     Mediator release  Eosinophils
                          B cell    T-helper cells                     Basophils      Priming
                                                                       Monocytes
                                    IL-4, IL-13 from TH-2              Lymphocytes
                                                     Nasal end organ (blood vessels, nerves, glands)

                         Plasma cell       Ig E
                                                     Sneezing, rhinorrhea, congestion, itching



             √Ÿª∑’Ë Ú ·ºπ¿Ÿ¡‘欓∏‘ √’√«‘∑¬“¢Õß°“√Õ—°‡ ∫®“°¿Ÿ¡‘·æâ : √–¬–·√° ¡’°“√ √â“ß IgE À≈—ß —¡º—  “√°àÕ¿Ÿ¡‘·æâ. √–¬–∑’Ë Ú ‡¡◊ËÕ¡’°“√ —¡º— 
                    “√°àÕ¿Ÿ¡‘·æâπ—ÈπÕ’° °Á®–‡°‘¥ªØ‘°‘√‘¬“μÕ∫ πÕß√–¬–μâπ ª√–°Õ∫¥â«¬°“√°√–μÿâπ ·≈–¡’°“√À≈—Ëß “√μ—«°≈“ß. À≈—ß®“°π—Èπ®–¡’
                   ‡´≈≈å·∑√°´÷¡ ∑”„À⇰‘¥°“√μÕ∫ πÕß√–¬–≈à“ ·≈–°“√μÕ∫ πÕ߇°‘πμàÕ ‘Ëß°√–μÿâπ∑’ˇªìπ·Õπ쑇®π ·≈–∑’ˉ¡à„™à·Õπ쑇®π. º≈¢Õß
                   °√–∫«π°“√¥—ß°≈à“« Õ“®À“¬‡Õ߉¥â À√◊Õ∑”„À⇰‘¥¿“«–·∑√°´âÕπ‰¥â.
   76   77   78   79   80   81   82   83   84   85   86